Ghisallo Capital Management LLC Cuts Stock Holdings in Acelyrin, Inc. (NASDAQ:SLRN)

Ghisallo Capital Management LLC cut its position in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 50.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 17,500 shares of the company’s stock after selling 17,500 shares during the period. Ghisallo Capital Management LLC’s holdings in Acelyrin were worth $77,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Acelyrin by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,237,543 shares of the company’s stock valued at $42,103,000 after purchasing an additional 81,633 shares in the last quarter. Millennium Management LLC increased its holdings in Acelyrin by 15.7% in the 2nd quarter. Millennium Management LLC now owns 4,642,056 shares of the company’s stock worth $20,471,000 after acquiring an additional 628,528 shares in the last quarter. Blue Owl Capital Holdings LP raised its position in Acelyrin by 3.5% during the second quarter. Blue Owl Capital Holdings LP now owns 2,926,028 shares of the company’s stock worth $12,904,000 after acquiring an additional 100,000 shares during the period. StemPoint Capital LP lifted its holdings in Acelyrin by 21.7% during the first quarter. StemPoint Capital LP now owns 714,773 shares of the company’s stock valued at $4,825,000 after purchasing an additional 127,400 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Acelyrin during the 1st quarter worth about $3,961,000. Institutional investors and hedge funds own 87.31% of the company’s stock.

Acelyrin Price Performance

Acelyrin stock opened at $5.09 on Wednesday. Acelyrin, Inc. has a 1-year low of $3.36 and a 1-year high of $10.70. The stock has a market cap of $508.03 million, a price-to-earnings ratio of -2.14 and a beta of 2.34. The firm has a 50 day simple moving average of $5.01 and a 200-day simple moving average of $5.07.

Acelyrin (NASDAQ:SLRN) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). During the same period last year, the firm posted ($0.56) earnings per share. Equities analysts expect that Acelyrin, Inc. will post -3.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on the company. HC Wainwright cut Acelyrin from a “buy” rating to a “neutral” rating and reduced their target price for the company from $18.00 to $6.00 in a report on Wednesday, August 14th. Wells Fargo & Company raised shares of Acelyrin from an “equal weight” rating to an “overweight” rating and set a $13.00 target price on the stock in a research note on Monday, July 8th. Piper Sandler reduced their target price on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Finally, Morgan Stanley lowered their price target on shares of Acelyrin from $13.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Monday, August 19th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.83.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.